UroGen Pharma
URGN
83 hedge funds and large institutions have $124M invested in UroGen Pharma in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 22 increasing their positions, 22 reducing their positions, and 7 closing their positions.
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
8% more funds holding
Funds holding: 77 → 83 (+6)
0% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 22
2.94% less ownership
Funds ownership: 65.68% → 62.75% (-2.9%)
12% less capital invested
Capital invested by funds: $140M → $124M (-$16.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.1M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$1.15M |
| 3 |
Millennium Management
New York
|
+$697K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$679K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$648K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
-$3.23M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.26M |
| 3 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
-$281K |
| 4 |
BlackRock
New York
|
-$213K |
| 5 |
Barclays
London,
United Kingdom
|
-$160K |
URGN Hedge Fund Activity: Q1 2022 in Review
83 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2022, worth a combined $124M — down 12% from $140M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new URGN positions and 7 closed out — a net gain of 7 holders — while 22 added to existing stakes and 22 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $2.1M. The largest seller was Zeke Capital Advisors, cutting an estimated $3.23M.
- 83 institutional investors held UroGen Pharma (URGN) as of Q1 2022, up from 77 in Q4 2021.
- Funds reported $124M of UroGen Pharma stock for Q1 2022, down 12% quarter-over-quarter.
- 14 funds opened new UroGen Pharma positions in Q1 2022 and 7 closed out, a net change of +7 holders.
- The largest UroGen Pharma buyer in Q1 2022 was Stonepine Capital Management, an estimated $2.1M added.
- The largest UroGen Pharma seller in Q1 2022 was Zeke Capital Advisors, an estimated $3.23M sold.
Based on aggregated 13F filings for Q1 2022.